Ascendis Pharma A/S
ASNDDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
31wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Once weekly subcutaneous injection of TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon CNP
Achondroplasia
Lonapegsomatropin
Growth Hormone Deficiency
TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon IL-2 β/γ
Advanced Solid Tumor
ACP-001 (TransCon hGH)
Adult Growth Hormone Deficiency
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Achondroplasia
ACP-001
Growth Hormone Deficiency (GHD)
Navepegritide
Achondroplasia
Somatropin
Turner Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Once weekly subcutaneous injection of TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon CNP | Phase 3 | Achondroplasia | - | - |
Lonapegsomatropin | Phase 3 | Growth Hormone Deficiency | - | - |
TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon IL-2 β/γ | Phase 2 | Advanced Solid Tumor | - | - |
ACP-001 (TransCon hGH) | Phase 2 | Adult Growth Hormone Deficiency | - | - |
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Phase 2 | Achondroplasia | - | - |
ACP-001 | Phase 2 | Growth Hormone Deficiency (GHD) | - | - |
Navepegritide | Phase 2 | Achondroplasia | - | - |
Somatropin | Phase 2 | Turner Syndrome | - | - |
Achondroplasia
3 drugs in this indication
Growth Hormone Deficiency (GHD)
1 drug in this indication
Adult Growth Hormone Deficiency
1 drug in this indication
Growth Hormone Deficiency, Pediatric
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)